Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Adds 10 Studies To, Bringing Total To 13

This article was originally published in The Pink Sheet Daily

Executive Summary

The 10 new Merck entries include three Phase III studies in type 2 diabetes. The company's listings are still relatively few when compared to its peers.

You may also be interested in...

Merck Support For ClinicalTrials.Gov Expansion Does Not Mean Company Will Add Listings

Merck says it prefers to continue to fly below the radar screen with respect to unless the law is changed. Merck's response to AMA's clinical trials registry proposal receives national media attention, but the company is an unlikely champion for government-sponsored public trial databases.

HHS Should Track All Rx Clinical Trials, AMA Says

All trials should be registered to ensure results are publicly available, physicians’ association says. Institutional review boards should not approve trials unless they are registered, AMA policy urges.

US FDA Expands Drug Development Tool Qualification Program With ISTAND Pilot

ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts